SAB Biotherapeutics (NASDAQ:SABS) Posts Quarterly Earnings Results

SAB Biotherapeutics (NASDAQ:SABS) issued its quarterly earnings results on Thursday. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is accelerating, with more than 60 sites actively recruiting and increased screening and randomization. Management remains on track to complete enrollment in Q4 2026, with top-line data expected in the second half of 2027.
• Breakthrough T1D awarded a grant supporting the PRISE-hATG Phase III study, which is expected to begin enrollment in the second half of 2026 across seven sites. If successful, the study could support a future SAB-142 label expansion for patients treated up to two years after diagnosis, with top-line data expected in Q1 2029.
• SAB Bio ended the quarter with $208 million in cash, cash equivalents, and investments, providing an operating runway through 2028. However, higher clinical-development and headcount costs drove R&D expense to $16.2 million and the net loss to $22.5 million, versus $10.1 million a year earlier.
• Management views the recent FDA approval of Tzield in recently diagnosed Stage 3 Type 1 diabetes as validation that C-peptide can support an accelerated-approval pathway. SAB Bio also highlighted SAB-142’s potential competitive advantages, including two-day dosing and low to no immunogenicity that may enable redosing.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock traded up $0.08 during mid-day trading on Thursday, hitting $3.85. 279,785 shares of the company traded hands, compared to its average volume of 513,660. SAB Biotherapeutics has a one year low of $1.85 and a one year high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The stock has a market cap of $294.37 million, a price-to-earnings ratio of -1.82 and a beta of 0.53. The stock has a fifty day moving average price of $3.68 and a 200-day moving average price of $3.83.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SABS shares. Jefferies Financial Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Chardan Capital boosted their price target on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Finally, Leerink Partners raised their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Institutional Trading of SAB Biotherapeutics

A number of hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC boosted its stake in shares of SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after purchasing an additional 11,344 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $322,000. OMERS ADMINISTRATION Corp bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth approximately $157,000. Verition Fund Management LLC bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $100,000. Finally, Marshall Wace LLP bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $884,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.